CIRM Funded Clinical Trials

First-in-human trial for EPI-321, a novel epigenetic therapy for FSHD targeting D4Z4 epigenome

Disease Area:
Muscular Dystrophy
Investigator:
CIRM Grant:
CLIN2-20392 (Pre-Active)
Award Value:
$8,000,000.00
Trial Sponsor:
Epicrispr Biotechnologies, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A